GGrantIndex
← Leaderboards

Brian C Vanderven

Cornell University

$7,523,719
Attributed
$7,523,719
Total exposure
5
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.3M · FY201325
$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$7,523,719 · 5

By mechanism

R01$7,098,094 · 4
R21$425,625 · 1

Top collaborators

No co-investigators on record.

Most similar at Cornell University

Same institution · by research overlap

Others in their field

Top investigators on “Bacteria

Research focus

BacteriaCessation Of LifeTuberculosisMacrophageCholesterolPathway InteractionsMycobacterium TuberculosisInfectionDrug DevelopmentPathogenesisMutantImmune ResponseDrug TargetingComplexGranulomaMetabolic PathwayIn VivoMouse ModelMetabolicPositioning AttributeImmuneEnzymesCholesterol HomeostasisVirulence

Grant awards (16)

Novel therapeutics to treat TB by stimulating bacterial cAMP production$746,602
R01 · FY2025 · AI · contact PI
Characterization of the nutrient assimilation pathways in M. tuberculosis$527,826
R01 · FY2025 · AI · contact PI
Characterization of the nutrient assimilation pathways in M. tuberculosis$598,288
R01 · FY2024 · AI · contact PI
Characterization of the nutrient assimilation pathways in M. tuberculosis$598,288
R01 · FY2023 · AI · contact PI
Characterization of the nutrient assimilation pathways in M. tuberculosis$640,202
R01 · FY2022 · AI · contact PI
Characterization of the nutrient assimilation pathways in M. tuberculosis$571,814
R01 · FY2021 · AI · contact PI
Preclinical evaluation of compounds that inhibit cholesterol uptake in M. tuberculosis.$440,175
R01 · FY2021 · AI · contact PI
Preclinical evaluation of compounds that inhibit cholesterol uptake in M. tuberculosis.$440,175
R01 · FY2020 · AI · contact PI
Preclinical evaluation of compounds that inhibit cholesterol uptake in M. tuberculosis.$456,622
R01 · FY2019 · AI · contact PI
Preclinical evaluation of compounds that inhibit cholesterol uptake in M. tuberculosis.$461,332
R01 · FY2018 · AI · contact PI
Preclinical evaluation of compounds that inhibit cholesterol uptake in M. tuberculosis.$454,270
R01 · FY2017 · AI · contact PI
Exploiting metabolic toxicities to identify compounds that inhibit cholesterol metabolism in M. Tuberculosis$387,500
R01 · FY2017 · AI · contact PI
Exploiting metabolic toxicities to identify compounds that inhibit cholesterol metabolism in M. Tuberculosis$387,500
R01 · FY2016 · AI · contact PI
Exploiting metabolic toxicities to identify compounds that inhibit cholesterol metabolism in M. Tuberculosis$387,500
R01 · FY2015 · AI · contact PI
Analysis of host-derived nutrient utilization pathways in M. tuberculosis$193,750
R21 · FY2014 · AI · contact PI
Analysis of host-derived nutrient utilization pathways in M. tuberculosis$231,875
R21 · FY2013 · AI · contact PI